$3.63
0.74% today
Nasdaq, Nov 04, 09:05 pm CET
ISIN
US57055L1070
Symbol
MRKR
Reports
Quarter | Annual
Index
NASDAQ Composite

Marker Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
●
3 months ago
Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study
Neutral
GlobeNewsWire
●
3 months ago
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma
Marker Therapeutics to receive non-dilutive funding from NIH Small Business Innovation Research Program based on preliminary clinical results and non-clinical data in lymphoma Marker Therapeutics to receive non-dilutive funding from NIH Small Business Innovation Research Program based on preliminary clinical results and non-clinical data in lymphoma
Neutral
GlobeNewsWire
●
6 months ago
Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now
The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today